NRP2 and ductal breast carcinoma in situ: Patient data regarding SEMA3F and its coreceptors NRP1 and NRP2 validate them as DCIS evolution prognosis markers for IDC and as new therapeutic targets, as has been previously described, to keep preinvasive BC lesions in this more therapeutically affordable BC stage.